Radiopharm Partners with Siemens Healthineers for RAD101 Phase 3 Clinical Supply

summarizeSummary

Radiopharm Theranostics has signed a clinical supply agreement with Siemens Healthineers for RAD101, ensuring manufacturing and distribution for its upcoming Phase 3 trial in the U.S. for brain metastases.

check_boxKey Events

• Clinical Supply Agreement Signed

  Radiopharm Theranostics has partnered with Siemens Healthineers for the radiolabeling and distribution of RAD101 (Fluorine-18 labeled) in the U.S.

• Ensures Phase 3 Trial Supply

  The agreement secures sufficient supply of RAD101 for the initiation of the multi-center global Phase 3 registrational trial in the U.S., following topline data readout from the Phase 2b trial in H1 2026.

• Positive Phase 2b Interim Data

  Interim analysis from the Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance with MRI (primary endpoint).

• FDA Fast Track Designation

  RAD101 has previously received U.S. Food and Drug Administration (FDA) Fast Track Designation for distinguishing recurrent disease from treatment effects in brain metastases.

auto_awesomeAnalysis

This agreement with Siemens Healthineers is a critical step for Radiopharm Theranostics, securing the manufacturing and distribution of RAD101 for its upcoming multi-center global Phase 3 registrational trial in the U.S. For a clinical-stage company, ensuring a reliable supply chain for a pivotal trial significantly de-risks the development pathway. The positive interim Phase 2b data, showing 90% concordance with MRI in brain metastases, combined with FDA Fast Track Designation, underscores the potential of RAD101. This partnership provides essential operational support as the company advances a key pipeline asset towards potential commercialization.